C0879262 - An oral fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-flurouracil (5-FU) activity, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, thereby inhibiting DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. CDHP is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyltransferase (the major enzyme responsible for 5-FU activation), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43548&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43548&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI

home UMLS 2020

293,031 терминов и синонимов из MeSH и LOINC

Поиск по CUI	Поиск по CODE
Поиск по одному или нескольким словам или частям слов

Lang Dictionary CODE		LUI	preferred no	SUI	preference Yes / No	Terms, descriptions
						CUI C0879262

	CHV			A18662350	AT130671691	a kind of cancer treatment drug
	CHV			A18662351	AT130671692	a kind of cancer treatment drug
	PDQ			A4358825	AT70647655	An oral fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-flurouracil (5-FU) activity, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, thereby inhibiting DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. CDHP is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyltransferase (the major enzyme responsible for 5-FU activation), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43548&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43548&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1833" NCI Thesaurus)